Posted by Michael Wonder on 05 May 2022
Aadi Bioscience announces unique permanent J code issued for Fyarro from Centers for Medicare and Medicaid Services
4 May 2022 - Effective 1 July J code will enable a streamlined reimbursement process for Fyarro.
Aadi Bioscience today reported it has received notification of a product-specific, permanent J code for Fyarro (sirolimus protein bound particles for injectable suspension) (albumin bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa).
Under the Healthcare Common Procedure Coding System, the J code (J9331) will become effective on 1 July 2022.
